Fulgent Genetics offers an asset-backed turnaround at a discount to tangible book, but billing execution and customer attrition must stabilize before the equity can re-rate.
Overview
**Fulgent Genetics combines a clinical laboratory business with a higher-risk oncology therapeutics platform**, using proprietary bioinformatics, molecular testing, pathology services, and nanoencapsulation technology. Diagnostics remains the economic engine, spanning Precision Diagnostics, Anatomic Pathology, and BioPharma Services, while FID-007 and FID-022 provide longer-term pipeline optionality. The company is attempting to replace pandemic-era COVID testing with recurring non-COVID volumes, aided by the Bako Diagnostics and StrataDx acquisitions and cross-selling opportunities. Q2 2026 revenue increased 20.1% sequentially to $85.4 million and 4.4% year over year, but missed consensus by $6.37 million because billing and revenue-cycle-management implementation delays impaired collections. Management cut 2026 revenue guidance to $330.0–$340.0 million and expects a non-GAAP operating margin near minus-25%. The investment case is primarily asset-backed: $551.5 million of cash, restricted cash, and marketable securities compares with approximately $526.64 million of market capitalization, while estimated net assets per share are $24.09–$29.00 versus a share price of approximately $18.55. Near-term catalysts are resolution of billing friction, receipt of the delayed $106.1 million IRS refund, continued pathology integration, and potential FID-007 Phase 3 entry in the first half of 2027. Analysts remain cautious, with a Hold consensus and targets ranging from $15.00 to $30.00.